Opportunity Information: Apply for RFA DA 25 060
The National Institutes of Health (NIH) is offering the "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" funding opportunity (RFA-DA-25-060) to support high-impact research that sits directly at the intersection of HIV and substance use. The central aim is to fund innovative projects that can open up new directions in HIV/AIDS research and generate practical advances in HIV prevention, treatment, and cure specifically for people who use drugs (PWUD). The FOA is designed for work that is ambitious and clearly positioned as "high priority," meaning applicants need to show that their proposed research addresses important gaps and has a strong potential to move the field forward.
A key requirement is that applications must present a detailed research plan backed by preliminary data and must explicitly explain the nexus between HIV and substance use. In other words, it is not enough to study HIV in general or substance use in general; the proposal needs to make a clear, defensible case for why substance use is central to the HIV-related scientific question, population, mechanism, intervention, or implementation challenge being studied. The program is also intentionally broad in the kinds of studies it will consider, welcoming approaches ranging from basic science through clinical research and on to implementation research. The "Clinical Trial Optional" label signals that projects may include a clinical trial if appropriate, but a clinical trial is not mandatory.
All proposed studies must align with the NIH HIV/AIDS Research Priorities described in NOT-OD-20-018, which outlines NIH-wide priorities and provides guidance for determining whether work qualifies as HIV/AIDS-focused for funding purposes. Practically, that means applicants should map their aims to those NIH HIV/AIDS priorities and make the alignment obvious in the narrative, rather than treating it as a general background reference.
Eligibility is broad and includes many types of U.S.-based organizations and government entities. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits (both with and without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses. The FOA also highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. However, the opportunity is not open to non-domestic (non-U.S.) entities applying as the primary applicant, and non-domestic components of U.S. organizations are not eligible to apply. At the same time, foreign components are allowed as defined by the NIH Grants Policy Statement, meaning a U.S. applicant may be able to include certain international elements if they meet NIH rules for foreign components.
The opportunity is categorized as a discretionary grant in the Education and Health funding activity area (CFDA 93.279). The posting lists an award ceiling of $1,500,000. The FOA was created on January 17, 2024, and the original closing date is February 11, 2027. Overall, this announcement is best understood as NIH seeking well-justified, data-supported, and clearly HIV-plus-substance-use-focused research that can produce meaningful scientific or public health advances for PWUD across the full continuum of discovery, clinical investigation, and real-world implementation.Apply for RFA DA 25 060
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2024-01-17.
- Applicants must submit their applications by 2027-02-11.
- Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) - RFA-DA-25-060
What is this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" (RFA-DA-25-060). It is intended to support high-impact research that sits directly at the intersection of HIV and substance use.
What is the main goal of the program?
The central aim is to fund innovative, high-priority projects that can open up new directions in HIV/AIDS research and generate practical advances in HIV prevention, treatment, and cure specifically for people who use drugs (PWUD).
What does NIH mean by "high priority" in this FOA?
In this announcement, "high priority" means the proposed research should address important gaps and have strong potential to move the field forward. Applications are expected to clearly show why the work is ambitious, timely, and likely to produce meaningful scientific or public health advances.
What kinds of research approaches are allowed?
The FOA is broad and welcomes studies across the full continuum, ranging from basic science to clinical research and implementation research, as long as the project is clearly centered on the HIV and substance use intersection.
Is a clinical trial required?
No. The FOA is labeled "Clinical Trial Optional," meaning projects may include a clinical trial if appropriate, but a clinical trial is not required.
What is the required focus on HIV and substance use?
Applications must explicitly explain the nexus between HIV and substance use. It is not sufficient to study HIV in general or substance use in general. The proposal needs a clear, defensible case showing why substance use is central to the HIV-related scientific question, population, mechanism, intervention, or implementation challenge being studied.
Do applications need preliminary data?
Yes. A key requirement is that applications include a detailed research plan backed by preliminary data.
What does "nexus between HIV and substance use" mean in practical terms?
It means the application should demonstrate that substance use is integral to the HIV-focused research aims. For example, the role of substance use should be central to the population being studied (PWUD), the biological or behavioral mechanism, the intervention strategy, or the real-world implementation problem the project is trying to solve.
Do projects have to align with NIH HIV/AIDS Research Priorities?
Yes. All proposed studies must align with the NIH HIV/AIDS Research Priorities described in NOT-OD-20-018.
How should applicants address NOT-OD-20-018 in their application?
Applicants should map their aims to NIH HIV/AIDS priorities and make the alignment obvious in the narrative. The FOA indicates this should not be treated as a general background citation; the connection to those priorities should be clearly explained.
Who is eligible to apply?
Eligibility is broad and includes many U.S.-based organizations and government entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits (with or without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses.
Are specific institution types highlighted as eligible?
Yes. The FOA highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Can a non-U.S. organization apply as the primary applicant?
No. The opportunity is not open to non-domestic (non-U.S.) entities applying as the primary applicant.
Can a U.S. organization with non-U.S. components apply?
Non-domestic components of U.S. organizations are not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, meaning a U.S. applicant may be able to include certain international elements if they meet NIH rules for foreign components.
What is the CFDA number and funding activity area?
The opportunity is listed under CFDA 93.279 and is categorized in the Education and Health funding activity area.
What is the maximum award amount mentioned in the posting?
The posting lists an award ceiling of $1,500,000.
What type of grant is this?
It is categorized as a discretionary grant.
What is the opportunity number and title that should be referenced?
The opportunity is identified as RFA-DA-25-060, titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)."
When was this FOA created?
The FOA was created on January 17, 2024.
What is the closing date for this opportunity?
The original closing date listed is February 11, 2027.
Who is the primary population of interest for impact?
The FOA emphasizes generating advances in HIV prevention, treatment, and cure specifically for people who use drugs (PWUD).
What is NIH looking for in successful applications?
NIH is seeking well-justified, data-supported, and clearly HIV-plus-substance-use-focused research that can produce meaningful scientific or public health advances for PWUD, across discovery, clinical investigation, and real-world implementation.
Browse more opportunities from the same category: Education, Health
Next opportunity: Minor Use Minor Species Development of Drugs (R01)
Previous opportunity: Spotlight on Humanities in Higher Education
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 25 060
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 25 060) also looked into and applied for these:
| Funding Opportunity |
|---|
| International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) Apply for PAR 24 114 Funding Number: PAR 24 114 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) Apply for PAR 24 122 Funding Number: PAR 24 122 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed Apply for PAR 24 113 Funding Number: PAR 24 113 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed) Apply for RFA DA 25 053 Funding Number: RFA DA 25 053 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trial Optional) Apply for RFA DA 25 032 Funding Number: RFA DA 25 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed) Apply for RFA DA 25 054 Funding Number: RFA DA 25 054 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Basic Experimental Studies with Humans (BESH) Required) Apply for RFA DA 25 033 Funding Number: RFA DA 25 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not Allowed) Apply for RFA DA 25 034 Funding Number: RFA DA 25 034 Agency: National Institutes of Health Category: Education, Health Funding Amount: $425,000 |
| Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional) Apply for PAR 24 118 Funding Number: PAR 24 118 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional) Apply for PAR 24 117 Funding Number: PAR 24 117 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trials Optional) Apply for RFA DA 25 043 Funding Number: RFA DA 25 043 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Long-Term Effects of Disasters on Healthcare Systems in Populations with Health Disparities (R01- Clinical Trial Optional) Apply for PAR 24 109 Funding Number: PAR 24 109 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial Optional) Apply for RFA OD 24 013 Funding Number: RFA OD 24 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $840,000 |
| Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) Apply for PAR 24 064 Funding Number: PAR 24 064 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Strategies to Improve Health Outcomes and Advance Health Equity in Rural Populations (R01 Clinical Trial Optional) Apply for RFA NR 24 005 Funding Number: RFA NR 24 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Disparities Among Women and Girls in Racial/Ethnic Minority and Other Underserved Communities (U34 Clinical Trials Required) Apply for RFA AA 24 006 Funding Number: RFA AA 24 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 24 007 Funding Number: RFA MD 24 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 005 Funding Number: RFA DA 25 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 004 Funding Number: RFA DA 25 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional) Apply for RFA CA 24 020 Funding Number: RFA CA 24 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 25 060", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.